Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Item
http://www.wikidata.org/entity/Q38962338
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerAberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast CancerPathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.Therapeutic siRNA for drug-resistant HER2-positive breast cancer.Clinical applications of mouse models for breast cancer engaging HER2/neu.mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancerNon-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic responseNonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.Virus-like particle display of HER2 induces potent anti-cancer responses.
P2860

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Item
http://www.wikidata.org/entity/Q38962338
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
@en
type
label
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
@en
prefLabel
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
@en
P2093
P304
P31
P356
10.1158/0008-5472.CAN-14-0983
P407
P433
P478
P50
P577
P698